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DiabetesThe ability of the heart muscle to derive energy from a wide variety of substrates provides the myocardium
with remarkable capacity to adapt to the ever-changing metabolic environment depending on factors
including nutritional state and physical activity. There is increasing evidence that loss of metabolic ﬂexibility
of the myocardium contributes to cardiac dysfunction in disease conditions such as diabetes, ischemic heart
disease and heart failure. At the level of glucose metabolism reduced metabolic adaptation in most cases is
characterized by impaired stimulation of transarcolemmal glucose transport in the cardiomyocytes in
response to insulin, referred to as insulin resistance, or to other stimuli such as energy deﬁciency. This review
discusses cellular mechanisms involved in the regulation of glucose uptake in cardiomyocytes and their
potential implication in impairment of stimulation of glucose transport under disease conditions. This article
is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism
and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Among the myocardial substrates, glucose accounts for less than 25%
of the energy production under normal conditions, with the majority of
energy being derived from fatty acid oxidation [1]. Glucose is however
unique among myocardial substrates because a small amount of ATP is
obtained by substrate-level phosphorylation during glycolysis even in
situations of hypoxia or ischemia. ATP obtained from glycolysis in the
extramitochondrial compartment, although scarce, may be of para-
mount importance for the maintenance or restoration of ionic homeo-
stasis, as discussed below.
Isolated rodent hearts perfused with buffer containing selected
substrate composition allow some insight in the impact of substrate
supply on cardiac function. Studies in Langendorff-perfused rat hearts
may suggest that glucose is dispensable for cardiac function in normal
circumstances. In fact, isolated rat hearts perfused aerobically for 2 h
with palmitate as the sole exogenous substrate performed equally well
as hearts perfusedwith glucose alone or both palmitate and glucose [2].
Similarly, hearts perfused with acetate and pyruvate functioned as well
as glucose-perfused hearts [3]. However, a limitation of such ex vivo
studies is the limited time during which glucose supply is shut off,
allowing glycogen stores to compensate, at least in part, for the lack of
exogenous glucose supply as suggested by the continued myocardialrdiomyocyte Biology: Cardiac
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l rights reserved.release of lactate [2]. Furthermore, on the long-term, glycolysis-derived
pyruvate might be required not so much for the production of acetyl-
CoA, which is alternatively obtained from β-oxidation of fatty acids, but
for the anaplerotic replenishment of Krebs cycle intermediates [4]. In
this process pyruvate instead of being converted to acetyl-CoA is
carboxylated either to oxaloacetate or malate to feed into the Krebs
cycle at intermediate steps [5].2. Importance of glucose in myocardial ischemia and reperfusion
The requirement for glucose for heart function becomes readily
apparent in situations of metabolic stress. In a previous study from our
laboratory, isolated perfused rat hearts were reperfused with medium
containing different concentrations of palmitate and glucose following a
period of 40 min of no-ﬂow ischemia [2]. Hearts reperfused in the
absence of glucose exhibited more pronounced post-ischemic contrac-
ture, less recovery of contractile function, and more release of creatine
kinase compared with hearts reperfused with medium containing
glucose with or without palmitate. Yet myocardial contents of ATP and
phosphocreatine during reperfusion indicated that hearts reperfused
with palmitate alone were on the whole not more energy depleted than
hearts reperfused with glucose in the presence or absence of palmitate.
In this study glycogen levels and rates of glycolysis were not determined.
However rates of glucose oxidation were measured and found to
correlate negatively with the severity of post-ischemic contracture.
To assess the role of glycolysis in the protective effects of glucose
Jeremy and coworkers took the approach of pharmacological inhibition
of glycolysis during ischemia and reperfusion of isolated rabbit hearts
[3,6]. For this purpose they used either iodoacetate or 2-deoxyglucose
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3-phosphate dehydrogenase (GAPDH), a key enzyme in the glycolytic
pathway [7]. 2-DG is transported into the cells by the glucose trans-
porters and phosphorylated to 2-deoxyglucose-6-phosphate (2-DG6P)
by hexokinase. 2-DG6P is a metabolic dead-end that cannot be further
metabolized, incorporated into glycogen or dephosphorylated. As
2-DG6P can neither cross the plasma membrane back, it accumu-
lates in the cardiomyocytes and competes with glucose-6-phosphate
for the catalytic site of phosphoglucose isomerase, thereby inhibiting
glycolysis. Rabbit hearts reperfused in the presence of either iodoace-
tate or 2-DG showed markedly impaired recovery of post-ischemic
function and aggravation of post-ischemic contracture. The authors
further demonstrated that impaired control of cytosolic Ca2+i, measured
by NMR-spectroscopy of the Ca2+-chelator 5F-BAPTA, during the ﬁrst
20 min of reperfusion was responsible for aggravation of reperfusion
injury during glycolytic inhibition. Although Ca2+i accumulation was
similar during ischemia in hearts exposed or not to iodoacetate, during
reperfusion Ca2+i accumulation subsided in control hearts but further
increased in iodoacetate-perfused hearts.
However, glucose is not only protective during reperfusion, but also
during ischemia with residual perfusion. In contrast to the above-
discussedmodels of no-ﬂow ischemia, the importance of glucose during
ischemia has been demonstrated in low-ﬂow ischemia experiments. This
model allows for control of substrate supply not only before and after
ischemia, but also during ischemia. Furthermore, low-ﬂow ischemia
results in, at least partial, washout of protons. Mallet and coworkers
induced low-ﬂow ischemia in guinea pig hearts perfused in the working
heartmode by lowering the coronary perfusion pressurewhile depleting
glycogen through the addition of norepinephrine to the perfusate [8].
Hearts perfused with medium containing glucose and pyruvate (both
5 mM) maintained residual spontaneous contractile activity throughout
ischemia, despite an 83% decline in coronary ﬂow, and contractile
activity recovered upon reperfusion. In contrast, when pyruvate was the
sole substrate, contractile activity nearly ceased after 10 min of ischemia,
and during reperfusion the heart was unable to resume contractile
function for more than 2 min, despite hyperemia. In additional exper-
iments glucose was present in the perfusate only during ischemia, added
oneminute before ischemia and removed oneminute before reperfusion,
with pyruvate being present all along. In this condition the hearts
maintained spontaneous contractile activity throughout ischemia, but
contractile function deteriorated to a complete stop within 5min of
reperfusion. The above studies in isolated heart preparations indicate that
the supply of glucose and glycolysis is essential during both low-ﬂow
ischemia, to maintain residual contractile activity, and post-ischemic
reperfusion, to support recovery of contractile function. An obvious
limitation of these ex vivo perfusion experiments is the all-or-none
approach to assess the effect of a selected substrate. Furthermore, it
needs to be emphasized that the absence of fatty acid in the perfusate in
some studies [3,6,8] may indeed be an ideal condition to demonstrate a
protective effect of glycolysis. In fact, Lopaschuk's group has shown that
fatty acid oxidation may attenuate or abolish the beneﬁcial effect of
glycolysis during ischemia and reperfusion by inhibition of oxidation of
glycolysis-derived pyruvate, resulting in production of lactate and
protons, which may favor transarcolemmal calcium inﬂux by Na+/H+
and Na+/Ca+ exchange [9]. Accordingly the protective effect of glucose
uptake and glycolysis largely depends on the coupling of glycolysis to
pyruvate oxidation. The present review focuses however on glucose
transport, and the interested reader is referred to an excellent recent
review in the same journal on the importance of myocardial oxidative
metabolism in ischemia and reperfusion injury [10].
In contrast to experiments using manipulation of substrate supply
during ex vivo perfusion of hearts from healthy rodents, appreciation of
the functional impact of impaired regulation of glucose transport, as is
observed in disease conditions with loss of metabolic ﬂexibility, which
include insulin resistance, diabetesmellitus andheart failure [11] ismore
difﬁcult. Interpretation of speciﬁc effects of altered myocardial glucosemetabolism is complicated by factors including concomitant modiﬁca-
tion of substrate supply in vivo and subsequent alteration of regulation of
alternate metabolic pathways in the myocardium [12]. For example,
insulin resistance in rodent models of diet-induced obesity or type 2
diabetes is characterized, at the level of the myocardium, not only by
defective glucose uptake, but also bymarked increase of fatty acid uptake
and oxidation which are likely to contribute to observed metabolic
changes and cardiac dysfunction, referred to as diabetic cardiomyopathy,
by mechanisms which are yet incompletely understood [13]. Recovery
of post-ischemic function was impaired during ex vivo perfusion
in hearts from insulin resistant db/db mice exhibiting reduced glucose
oxidation and increased palmitate oxidation [14]. Interestingly,
both glucose oxidation and recovery of contractile function were
improved by increasing glucose and insulin concentration in the
perfusate, compatible with a role of insufﬁcient glucose supply in post-
ischemic cardiac dysfunction. Consistent with a role of intact glucose
transport in post-ischemic recovery of contractile function are obser-
vations in hearts from transgenic mice with cardiac-selective GLUT4
deﬁciency, which also exhibit impairment of post-ischemic contractile
recovery [15].3. Glucose transport and transporters
The ﬁrst step of glucose metabolism is the transport of glucose
across the plasma membrane. Glucose transport occurs by facilitated
diffusion through selective transport proteins of the GLUT family. The
gradient of glucose concentration across the plasma membrane drives
the inﬂux of glucose. The gradient is maintained because hexokinase
phosphorylates glucose as it enters the cardiomyocytes and the capacity
of hexokinase, at least in control conditions, exceeds that of glucose
transport. In cardiomyocytes, mostly two isoforms of glucose trans-
porter, GLUT1 and GLUT4, are involved. GLUT1, which predominates
during fetal and early postnatal life [16] is located mainly in the
sarcolemma under basal conditions [16,17]. GLUT4 on the other hand is
the main isoform present in fully differentiated cardiomyocytes and is
expressed in tissues that respond to insulin by increasing glucose
transport. GLUT4 is mainly located in intracellular membrane compart-
ments and is translocated to the cell surface in response to stimuli
including increased workload, ischemia, catecholamines and insulin
[18–22]. Despite similar structures and enzymatic turnover numbers,
GLUT4 has a higher afﬁnity for glucose (Km≈4–7 mM) than GLUT1
(Km≈20–26 mM) [23,24]. This characteristic combined with its greater
expression in cardiomyocytesmakes GLUT4 responsible for themajority
of glucose uptake, even in the basal state. As a result, the major
determinant of glucose uptake into cardiomyocytes at physiological
glucose concentrations (4–7 mM) is the number of GLUT4 transporters
present at the cell surface.
The crucial role of GLUT4 is illustrated in experiments with
measurement of basal and insulin-stimulated glucose uptake in
isolated perfused mouse hearts with heart-speciﬁc ablation of the
glut4 gene [15]. In hearts from wild-type mice insulin induced a rapid
and marked stimulation of glucose uptake that was absent in GLUT4-
deﬁcient hearts.
Although GLUT4 is the predominant isoform of glucose transporter
present in the normal myocardium, GLUT1 acquires relatively more
importance in chronic or semi-chronic pathophysiological situations
where GLUT1 expression is increased, sometimes concomitantly with
repression of GLUT4. Such pathophysiological situations in rodents
include post-ischemic reperfusion [25], post-infarction heart failure
[26] and pressure overload hypertrophy [27]. At an artiﬁcial extreme,
knocking-out of glut4 in the murine myocardium leads to a marked
3-fold overexpression of GLUT1 [28]. These instances of partial or
complete functional replacement of GLUT4 with GLUT1 are charac-
terized by a loss of metabolic ﬂexibility, with increased myocardial
basal glucose uptake and reduced or abolished insulin responsiveness.
F-actin α-tubulinGLUT4 merge
A
B
Fig. 1. Cytoskeletal organization and GLUT4 distribution in cardiomyocytes.Immuno-
ﬂuorescence confocal imaging of F-actin (red), GLUT4 (green) and α-tubulin (blue) in
ex vivo cardiomyocytes (A) and in cardiomyocytes kept in culture for 3 days in the
presence of 9-cis retinoic acid (B). Scale bars: 10 μm.
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Similarly to adipose tissue and skeletalmuscle (reviewed in [29]), the
transarcolemmal transport of glucose into cardiomyocytes is acutely
regulated mostly by the translocation of the glucose transporter GLUT4.
In basal states with low glucose transport rates, GLUT4 is retainedwithin
intracellular membrane structures where it does not participate in
glucose transport. The identity of this compartment is not entirely
deﬁned but appears to be a specialized subcompartment of the post-
Golgi network [30]. In cardiomyocytes two separate populations of
GLUT4-containing vesicles have been identiﬁed on the basis of their high
or low content of both GLUT1 and secretory carrier membrane proteins
(SCAMP), which are markers of the endosomal compartment [31].
Functionally, however, both populations of GLUT4 are recruited by
insulin. It should be noted that GLUT4 does not permanently remain in
its intracellular stores in unstimulated cells, but continuously recycles
with the cell surface, albeit at low rates. By immunoﬂuorescence, the
internal GLUT4 compartments appear distributed throughout the
cytoplasm, but are more prominent in perinuclear locations (Fig. 1A).
3.2. Insulin signaling
Insulin by far is the most thoroughly studied stimulus that triggers
translocation of GLUT4 from intracellular stores to the cell surface.
Binding of insulin to its receptor (IR) activates autophosphorylation of
the receptor's β subunits on tyrosine residues and subsequently
phosphorylation of tyrosine residues on the insulin receptor substrate
proteins (IRS-1, -2 and ‐3) (reviewed “at a glance” in [32] and more
speciﬁcally for the heart in [33]). In turn, phosphorylated IRS associate
with and activate phosphoinositide 3-kinase (PI3K), whose product,
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruits and activates
another kinase, phosphoinositide-dependent protein kinase 1 (PDK1,
also abbreviated PDPK1) in the vicinity of the plasma membrane. PDK1
activation leads to the phosphorylation of the protein kinase Akt,
formerly known as PKB, on the key residue Thr308 [34] while the
mTORC2 (mammalian target of rapamycin complex 2) complex
phosphorylates Ser473 [35]. The combination of the two phosphor-
ylations on Akt results in a 50-fold stimulation of Akt kinase activity
[36]. Akt exists in three isoforms, Akt1, -2 and ‐3, of which Akt2
mediates the metabolic effects of insulin [37,38], whereas Akt1 activity
governs cardiomyocyte size [39].
Activation of the mTORC1 complex leads to dowregulation of IRS-1
[40,41] through phosphorylation of multiple serine residues. This
mechanism has been invoked to contribute to myocardial resistance
in type II diabetes [42]— see Section 4. As the mTORC1 complex is itself
activated in response to insulin and Akt activation [43], this constitutes
a negative feedback loop, the inhibition of which should reinforce
stimulation of glucose transport in response to insulin. Indeed in
cardiomyocytes [44] as in skeletal muscle myotubes [45] activation of
the AMP-activated kinase (AMPK) inhibited mTORC1 complex activity
and improved both insulin signaling and insulin-stimulated glucose
transport. However in cardiomyocytes selective inhibition of mTORC1
activity with rapamycin failed to increase insulin-stimulated glucose
transport although insulin signaling as assessed by Akt and AS160
phosphorylation was improved. This indicates, ﬁrst, that additional
effects of AMPK activation on as yet unidentiﬁed mechanisms are
required for the potentiation of insulin action on glucose transport, and,
second, that activation of Akt2 and AS160 axis is not a rate-limiting step
in the regulation of cardiac glucose uptake downstream of insulin.
The Rab GTPase-activating protein AS160 (also known as TBC1D4)
has recently been identiﬁed as a substrate of Akt2 [46,47], which upon
phosphorylation dissociates fromGLUT4-containing vesicles, a required
step for the insertion of GLUT4 in the plasma membrane [48]. Another
protein from the same family, TBC1D1, plays a similar role in skeletal
muscle [49], but does not seem to be involved, or even present at
signiﬁcant levels, in cardiomyocytes.Rab proteins are regulators of intracellular vesicular transport [50],
and as such are involved in the mechanisms of GLUT4 translocation
[51]. The constitutive GTPase-activating activity of AS160 keeps Rab
proteins inactive. Phosphorylation of AS160 inactivates its GTPase-
activating function and thereby enables activation of Rab proteins.
Several Rab proteins are associated with GLUT4-containing vesicles in
adipocytes and thus are susceptible to be activated once AS160 is
inactivated by phosphorylation [48,52]. The speciﬁc complement of Rab
proteins that participate in GLUT4 vesicles trafﬁcking in cardiomyocytes
only begins to be investigated. To date only Rab11 has been consistently
shown to contribute to GLUT4 trafﬁcking in the heart [53–55]. AS160
however does not inactivate Rab11 [52].
It needs to be emphasized that translocation of GLUT4 is not simply
the result of one single linear pathway activated by insulin binding to its
receptor. Other branching or parallel pathways have been suggested to
contribute as well, although they are much less well deﬁned. Atypical
protein kinases C (aPKC) are the PKC isoforms that require neither Ca2+
nor diacylglycerol for their activation [56]. Two aPKC isoforms, λ and ζ,
have been reported to be activated in adipocytes and skeletal muscle
myocytes by insulin, through PDK1-mediated phosphorylation [57],
and thereby to participate in the translocation of GLUT4 and hence in
the stimulation of glucose transport [58–60]. However this concept has
been challenged by some investigators who have reported either no
signiﬁcant role [61] or even a negative regulatory role of aPKC [62]. Very
little information is available on the role of aPKC in glucose transport in
cardiomyocytes. In vivo, insulin-stimulated glucose uptake is markedly
reduced in PKCλ-knockout myocardium [63]. In vitro, it was observed
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nevertheless required for GLUT4 translocation to occur [64]. Thus the
role of PKCζ in the stimulation of glucose transport by insulin in
cardiomyocytes is permissive rather than stimulatory.
Another insulin-triggered signaling pathway has been suggested to
contribute to the translocation of GLUT4 (Fig. 2). In adipocytes insulin
receptor-mediated tyrosine phosphorylation of the proto-oncogene Cbl
and the adaptor protein APS, the association of Cbl with Cbl-associated
protein (CAP) and translocation to lipid rafts, independently of the PI3K
cascade, appeared to be required for translocation of GLUT4 in response
to insulin [65–67]. In contrast, in skeletal myocytes Cbl is present but
does not seem to participate in GLUT4 translocation [68]. Our own
studies seemed to indicate an important role for Cbl in cardiomyocytes as
well [69]. Indeed, we observed in cardiomyocytes undergoing transient
dedifferentiation and insulin resistance in long-term culture a marked
correlation between Cbl expression, Cbl phosphorylation and insulin
responsiveness. Other studies have since cast serious doubts on the
importance of the CAP/Cbl pathway for insulin action on glucose
transport. In fact, Cbl-deﬁcientmice present improved peripheral insulin
action [70], whereas Cbl knockdown in adipocytes failed to attenuate
insulin-stimulated glucose transport [71]. However neither study
investigated what happens in cardiomyocytes when Cbl expression
is repressed.
3.3. Metabolic stress and AMPK
Although best characterized, insulin is not the only trigger that
induces the translocation of GLUT4. Activation of AMPK system also
elicits translocation of GLUT4 [22], by mechanisms that only partiallyIRαIRα
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of a dominant-negative mutant of CaMKKβ partially inhibited the
translocation of GLUT4 in response to oxidative stress in cardiomyocytes
[83], indicating that this mechanism is operative in addition to stress-
induced increase of AMP/ADP alone. We are currently investigating the
implication of CaMKII in the stimulation of glucose transport triggered by
cardiotrophin-1.
Activation of AMPK has been proposed to mediate the effects of
ischemia [84] and increased workload [85], two conditions leading to
GLUT4 translocation in the myocardium [18–20,86]. However some
investigators found no AMPK activation in response to increased
workload either in isolated perfused hearts [87] or in vivo [88]. Thus
whether AMPK is activated by a physiological increase inworkload in the
heart and whether this explains increased glucose transport remains
controversial to date. Indeed, contraction-induced glucose uptake and
GLUT4 translocation were observed in cardiomyocytes from AMPK2α-
null mice, despite markedly reduced AMPK activation [89]. It was
suggested that contraction elicitedAMPK-independent activation of PKD,
also known as protein kinase C μ , and that activated PKD could trigger
translocation of GLUT4. Further investigation showed that reactive
oxygen species (ROS)-induced activation of the death-activated protein
kinase (DAPK) mediated PKD activation and stimulation of glucose
transport [90]. Therefore AMPK plays a central, but possibly not unique,
role in the stimulation of glucose transport in response to either
physiological (increased workload) or pathological (ischemia) metabolic
stress.
3.4. Role of intracellular calcium
Calcium is a major intracellular signal in almost all cell types. In
cardiomyocytes the most readily apparent effect related to calcium
signaling is cellular contraction. Since the force of contraction is
determined by the amount of calcium released during calcium
transients, it would make sense if the same calcium signals were
involved in regulation of cellular glucose uptake, thereby matching
energy provision and consumption. For instance CaMKII activation,
leading to AMPK activation and stimulation of glucose transport
(see above), integrates the frequency and amplitude of Ca2+i spikes, at
least in neurons [91]. There is good reason to believe that it does so in
cardiomyocytes as well [92,93].
The role of calcium in the insulin response has been controversial
from the very beginning. Some investigators reported no effect of
varying concentrations of extra- or intracellular calcium on the insulin
response [94,95] while others found that omitting calcium from the
incubation medium reduced stimulation of glucose uptake by insulin by
almost 75% [96]. The controversy was disregarded for more than
20 years and readdressed only recently [97]. In neonatal quiescent
cardiac myocytes insulin evoked a biphasic intracellular calcium (Ca2+i)
response mediated successively by activation of the L-type calcium
channel and by generation of inositol-1,4,5-trisphosphate (IP3). Phar-
macological interventions designed to either buffer Ca2+i or prevent the
second, IP3-dependent, but not the ﬁrst, phase of the Ca2+i response
reduced insulin-stimulated glucose uptake and prevented GLUT4
translocation. Remarkably, GLUT4 translocation in response to 2,4-
dinitrophenol, an uncoupler of oxidative phosphorylation, was im-
mune to Ca2+i manipulation. As the glucose transport response to 2,4-
dinitrophenol is mediated by AMPK activation [98], this suggests that
only the effect of insulin on glucose transport, but not the effect of
metabolic stress, is dependent on Ca2+i. It remains to be seen, ﬁrst, how
signiﬁcant such a second-messenger-, namely IP3-, triggered Ca2+i
signal would be in the context of the large cyclic variations of Ca2+i in
the beating myocardium and, second, whether the amplitudes of the
cyclic variations of Ca2+i in the beatingmyocardium are by themselves
suitable signals to inﬂuence glucose transport. Perhaps in this context,
as in others [99,100], calcium microcompartmentalization will prove
important.3.5. Role of nitric oxide
In addition to the above-mentioned pathways, it appears that
production of nitric oxide (NO) by a nitric oxide synthase (NOS) is
required for insulin action in some tissues, including the heart [101].
Furthermore, translocation of GLUT4 in response to AMPK activation in
cardiacmuscle involves NOS activation andNOproduction [102]. Indeed,
both activated Akt [103] and AMPK phosphorylate and activate eNOS
[104]. In adipocytes NO donors stimulate glucose transport and GLUT4
translocation in the absence of insulin or of PI3K activation [105]. Thus,
available evidence points to a crucial role of NO in the translocation of
GLUT4. In vivo observations also indicate that some level of production of
NO seems to be required for normal insulin sensitiveness in several
tissues including the heart (reviewed in [106]). Indeed, mice with
ablation of both the eNOS and nNOS are insulin-resistant [107], while
partial deletion of eNOS predisposes for diet-induced insulin resistance
[108]. Furthermore, NOS inhibition prevents the improvement of insulin
action brought about by PPARγ agonist treatment [109]. In contrast,
excessive NO production as occurs during inﬂammatory response is
deleterious to insulin sensitiveness [110]. The cellular mechanism of NO
action is presently unknown.3.6. Role of the cytoskeleton in GLUT4 translocation
Translocation of GLUT4 storage vesicles towards the cell surface
does not occur in a void and is highly dependent on cytoskeletal
structures. In adipocytes and skeletalmyocytes insulin induces dynamic
remodeling of cortical actin [68,111] that participates in GLUT4
translocation. This effect is mediated through activation of the small
G-Protein TC10 in adipocytes [112], but not in skeletal myocytes [68].
The importance of an intact and dynamic microtubule network for the
stimulation of glucose transport by insulin has been extensively studied
in adipocytes [113,114]. Strikingly, in adipocytes a dense microtubule
network is rapidly assembled in response to insulin [115]. In contrast,
themicrotubule network preexists before insulin stimulation of skeletal
muscle myocytes and does not appear to be that important in this cell
type [116]. We observed that cardiomyocytes exhibit a somehow
intermediate behavior between these two cell types: similar to skeletal
myocytes, an extensive microtubule network exists prior to insulin
stimulation (Fig. 1A), but as in adipocytes, disruption of the network
completely prevents insulin-mediated stimulation of glucose uptake
[117].We could demonstrate that microtubuleswere crucially involved
in conveying insulin- ormetabolic stress-triggered signaling to AS160, a
key protein in the regulation of GLUT4 translocation. In isolated cultured
cardiomyocytes disruption of microtubules occurs spontaneously within
2 to 3 days and is particularly prominent at the microtubules organizing
centers (MTOC). It is prevented by addition to the culture medium of
9-cis retinoic acid (9cRA; Fig. 1B). Activation of ERK1/2 MAP kinase
occurring during cardiomyocytes isolation [118] may impact on
microtubule stability [119]. Retinoic acids may accelerate ERK1/2
deactivation by enhancing expression of MAPK phosphatases [120].
We could indeed show that cardiomyocytes exposed to inhibitors of
the ERK1/2 kinases mitogen/extracellular signal-regulated kinase 1/2
(MEK1/2) had preserved microtubular scaffold, including MTOCs,
associated with increased insulin and metabolic stress-stimulated
signaling and glucose transport, thus replicating the effects of 9cRA
treatment [121]. Although 9cRA treatment did not signiﬁcantly reduce
total cellular ERK1/2 activation, it markedly reduced activated ERK1/2 at
the perinuclear location ofMTOC. In contrast to our results, Steinbusch et
al. reported since that microtubule disruption had no effect on
stimulated glucose transport [122]. Microtubule and MTOC disrup-
tion with colchicine appeared however much less dramatic in their
hands than in our experiments, perhaps explaining this discrepancy.
Finally we observed in cardiomyocytes chronically exposed to free fatty
acids and exhibiting impaired stimulation of glucose transport, disruption
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between these observations remains to be further investigated.
4. Insulin resistance in the myocardium
Insulin resistance of the myocardium, considered here only in terms
of glucose uptake, was identiﬁed in isolated perfused hearts obtained
from diabetic Zucker obese fa/fa rats almost three decades ago [124]. The
corresponding observation in the human myocardium had to await the
advent of [18F]-ﬂuorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) [125]. Impaired stimulation of glucose transport in response to
insulinwas observed in various animalmodels of type II diabetes andhas
allowed identiﬁcation of a number of molecular defects. However, the
overall picture remains incomplete with several contradictory observa-
tions. Following the initial observation of Zaninetti et al. [124], the Zucker
fa/fa obese rats [126] were extensively studied as a model of myocardial
insulin resistance using either isolated perfused heart preparations
or isolated cardiomyocytes in culture [86]. Even in this single model,
contradictory results have emerged. Insulin-stimulated glucose transport
was found by some authors to be markedly inhibited in perfused hearts
[124], while others observed severe reduction in isolated cardiomyocytes
but only marginal reduction in perfused hearts [127,128], an observation
attributed to the quiescent state of isolated cardiomyocytes. In the study
by Kolter et al. insulin resistance in isolated Zucker fa/fa cardiomyocytes
was attributed to diminished insulin sensitiveness, characterized by
a preserved response to a supraphysiological dose of insulin [42].
Conversely, Huisamen et al. have observed diminished insulin respon-
siveness [128], characterized by reduced glucose transport even at a
supraphysiological dose of insulin. Regarding insulin signaling in
cardiomyocytes of the Zucker fa/fa rat, both increased inhibitory
phosphorylation of IRS-1 on serine and threonine residues and
reduced activating phosphorylation of Akt [127] were observed. The
latter is readily explained by the reduced recruitment and activation
of PI3K by IRS-1 [42]. Again this was only observed at submaximal
insulin concentrations. Downstream of insulin signaling, defective
GLUT4 translocation to the cell surface aswell as reduced translocation of
Rab4 from the cytosol to the membrane have been observed [129]. Later
studies indeed indicated the participation of Rab4 in the regulation of
glucose transport by insulin [130] but the detailed cellular mechanism
remains to be determined. The picture is slightly different in another
model of type II diabetes in the rat, the Goto-Kakizaki rat [131]. In
isolated perfused hearts from this non-obese model, resistance of
glucose transport to stimulation by insulin was associated with reduced
expression of GLUT4, insulin receptor β and IRS-1, but with preserved
phosphorylation of these signaling intermediates, and most remarkably
unaffected expression andphosphorylation ofAkt [132]. Therefore results
from thismodel reinforce the above-mentioned concept (see Section 3.2)
that activation of Akt is not rate limiting for stimulation of glucose
transport by insulin in the heart [44]. The relatively modest reduction of
GLUT4 expression in rat models of type II diabetes [127,129,132–134] is
unlikely to signiﬁcantly contribute to insulin resistance, as full insulin
response was preserved in isolated hearts withmarkedly reduced GLUT4
expression [135].
Research in hearts or cardiomyocytes from mouse models of
insulin resistance has been initially delayedmainly because of technical
challenges imposed by the smaller hearts. However, ongoing work in
transgenic models of insulin resistance is likely to provide new insight
in molecular mechanisms. In cardiomyocytes from the obese diabetic
db/db mice, insulin-stimulated glucose transport was impaired with a
reduction of insulin responsiveness, not sensitiveness. This defect was
associated with a decreased phosphorylation of Akt [136].
The possibility offered by the culture of isolated cardiomyocytes of
precisely controlling the cellular environment has motivated research
efforts to replicate myocardial insulin resistance observed in vivo in
such in vitro models, in order to further investigate the cellular and
molecular mechanisms involved. Impaired stimulation of glucosetransport in response to insulin was observed in cultured cardiomyo-
cytes in several conditions, including spontaneous dedifferentiation
[69], chronic β-adrenergic stimulation [137] and chronic exposure to
insulin [138,139], Leukemia Inhibitory Factor (LIF) [140], ketone bodies
[141], angiotensin II [142] or TNFα [143]. In addition, our group
observed insulin resistance in adult rat cardiomyocytes chronically
exposed to PPARα or PPARδ agonists, free fatty acids (FA) [123] or to
VLDL [144]. Interestingly, the mechanisms responsible for FA-induced
insulin resistance in cardiomyocytes appeared to be different from
those observed in skeletal muscle or muscle cell lines. In fact, in skeletal
muscle cells in culture, insulin resistance develops in response to the
saturated FA palmitate, but is prevented by concomitant incubation
with themonounsaturated FA oleate [145–147]. In contrast we observed
insulin resistance in cardiomyocytes exposed to either palmitate or
oleate, or both concomitantly [123], the latter situation being closest to
in vivo conditions [148]. Further, neither of themetabolites proposed to
mediate FA-induced insulin resistance in skeletalmuscle cells, including
ceramides [149,150], acylcarnitines [151], lysophosphatidylcholine [152]
or diacylglycerols [153] could be invoked in cardiomyocytes. Clearly
cardiomyocytes differ from skeletal myocytes and additional studies are
needed to further decipher the mechanisms of FA-induced insulin
resistance in the heart.
Impairment of the stimulation of glucose transport in response to
metabolic stress has received much less attention. Given its pathophys-
iological importance [84], a reduction of this response may very well
explain why patients with metabolic syndrome have more extensive
myocardial damage during myocardial infarction [154]. Impaired
myocardial stimulation of glucose transport by ischemia has been
reported in some models of type II diabetes [134,155] and indeed was
associated with increased ischemic injury. We studied the effect of
metabolic inhibition by 1 μM oligomycin in isolated rat cardiomyocytes
with FA-induced insulin resistance. Oligomycin inhibits oxidative
phosphorylation of ADP to ATP, thus leading to cellular metabolic stress,
activation of AMPK and stimulation of glucose transport independently
of and additively to insulin signaling [90,121,139,156]. Oligomycin is
therefore a better in vitro surrogate of ischemia than direct AMPK
agonists such as AICAR. In fact such direct AMPK agonists are much less
potent stimulators of cardiomyocytes glucose transport than oligomycin,
presumably because oligomycin activates parallel stimulating pathways,
including PKCμ/PKD [90], in addition to AMPK. Similar to observations
with insulin stimulation, oligomycin-stimulated glucose transport
(OSGT) was profoundly reduced after exposure to either palmitate,
oleate or both [123]. The fatty acid metabolite(s) responsible for this
effect remains unidentiﬁed, but appears to differ from that mediating
reduced insulin responsiveness. Pharmacological manipulation of FA
oxidation rates in isolated cardiomyocytes led us to the conclusion that
the metabolite responsible for OSGT impairment was possibly an
intermediate of FA oxidation. Recent evidence suggests that lipid
intermediates originating from incomplete fatty acid oxidation could
induce insulin resistance in the skeletal muscle [151] and in the heart
[157]. However it has to date only been linked with mitochondrial
dysfunction in insulin resistance, not transarcolemmal glucose transport.
On the other hand we observed restoration of OSGT in cardiomyocytes
exposed to both FA and a broad-spectrum PKC inhibitor, with no effect
on insulin responsiveness. This suggests that activation of some PKC
isoform is responsible for the reduction of OSGT in FA-exposed
cardiomyocytes. Accordingly increased accumulation of diacylglycerol
may be the culprit for the reduction of OSGT. The dichotomy of FA
effects on insulin- and metabolic stress-stimulated glucose transport in
cardiomyocytes further suggests multiple points of impacts in the
cellular mechanisms leading to GLUT4 translocation.
5. Conclusions
The mechanisms of GLUT4 translocation and consequent stimula-
tion of glucose transport have been extensively studied in adipose
854 C. Montessuit, R. Lerch / Biochimica et Biophysica Acta 1833 (2013) 848–856tissue and skeletal muscle, which, by sheer bulk, are the premier
metabolic targets of insulin. Clearly, conclusions obtained from these
two organs cannot be simply extrapolated to the myocardium. The
cardiac myocyte has its peculiarities, warranting additional research
efforts to further decipher the regulation of glucose transport in the
myocardium. Stimulation of glucose transport by metabolic stress is
of particular relevance in the myocardium, because it profoundly
inﬂuences myocardial survival and recovery in disease conditions.
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